2023年6月16日

平息跡象細胞療法與阿斯利康合作集中在自身免疫性疾病主要亮點:協作開發,製造和商業化設計t調節細胞(Treg)治療自身免疫性疾病兩個方麵—1型糖尿病和炎症性腸病。平息收到8500萬美元的前期包括主要現金支付和股權投資,與潛在的支付超過20億美元的取決於開發和商業的裏程碑,加上分層的版稅。協議進一步驗證Syncona的模型,能夠創建具有全球競爭力的企業。Syncona有限公司宣布平息療法(鎮壓),一個領導者在發展中設計t調節細胞(Treg)治療嚴重疾病的免疫係統,和阿斯利康,進入了一個協作、獨家選項和許可協議開發,製造和商業化自體,工程Treg細胞治療兩個自身免疫性疾病跡象。根據協議條款,平息的專用工具箱Treg細胞工程模塊,包括其Foxp3表型鎖,將杠杆開發自體multi-modular Treg細胞療法候選人1型糖尿病和炎症性腸病。阿斯利康可以選擇進一步發展和商業化成功的候選人,以平息負責臨床候選人的過程開發和製造first-in-human臨床研究結束。平息將繼續保留的全部所有權的領導計劃qel - 001,這是一個Treg細胞療法的候選人被開發為肝移植手術患者預防器官排斥和終身免疫抑製的必要性。×平息將獲得8500萬美元的前期阿斯利康由主要現金支付和股權投資。此外,平息將有資格獲得潛在的支付總額超過20億美元,取決於成功地達到發展和商業的裏程碑,加上分層的版稅。此外,平息保留一個選項,可以行使批準後的試驗性新藥(印第安納州)的應用程序或I / II期臨床研究中,共同開發Treg細胞療法的1型糖尿病與阿斯利康項目在美國,以換取額外的裏程碑付款和增加了美國網絡銷售的版稅。 Following the signing of the agreement, Syncona's ownership stake in Quell is 33.7 per cent, whilst the valuation for this holding is unchanged at $107.0 million (£86.7 million). Martin Murphy , Chair of Syncona Investment Management Limited and Chair of Quell Therapeutics, said: “We are excited that Quell has attracted AstraZeneca to partner with them on the development of innovative Treg cell therapies. AstraZeneca’s expertise and capability will be instrumental in driving these important programmes forward through the development pathway. In a challenging financing environment for biotech companies, I am particularly pleased to see Quell attract this level of financing to drive their programmes forward." “The collaboration is further validation of the Syncona model and the quality of companies that we can create, build and scale from our leading academic network. I look forward to seeing the impact of the partnership on the speed at which we can bring these ground-breaking therapies to patients.” Iain McGill , Chief Executive Officer of Quell Therapeutics commented: “We are extremely pleased to have AstraZeneca on board as our first major partner. This collaboration builds on our pioneering work to develop exquisitely engineered, multi-modular Treg cell therapies for immune disorders and provides excellent validation for the technologies and capabilities we have established.” “We are proud and incredibly excited to partner our leading science with the deep experience of AstraZeneca to accelerate the application of our Treg cell therapy platform in major autoimmune disease, where we believe there is a broad opportunity to reset immune tolerance and drive durable responses for patients.”